SCHEMBL10104479

SCHEMBL10104479

Cc1cc(CN2CCCC2)c(F)c(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.43
ALDH1A1 P00352 7/20 0.43
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
NR1H2 P55055 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
ATM Q13315 3/20 0.39
NPSR1 Q6W5P4 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GAA P10253 3/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
CRHR1 P34998 1/20 0.38
SCN9A Q15858 1/20 0.37
CACNB4 O00305 1/20 0.37
CACNA1A O00555 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10104533 0.86 KDM4E (0.44) KDM4EALDH1A1POLBSMN1; SMN2NR1H2
SCHEMBL10104480 0.84 KDM4E (0.43) KDM4EALDH1A1POLBSMN1; SMN2NR1H2
SCHEMBL10104431 0.83 KDM4E (0.43) KDM4EALDH1A1POLBNR1H2SIGMAR1
SCHEMBL10104460 0.82 KDM4E (0.43) KDM4EALDH1A1POLBSMN1; SMN2NR1H2
SCHEMBL10104525 0.81 MEN1 (0.44) KDM4EALDH1A1POLBNR1H2SIGMAR1
SCHEMBL10104470 0.80 KDM4E (0.46) KDM4EALDH1A1POLBNR1H2SIGMAR1
SCHEMBL14426354 0.79 KDM4E (0.51) KDM4EALDH1A1POLBNR1H2SIGMAR1
SCHEMBL12426532 0.79 NR1H2 (0.55) KDM4EALDH1A1POLBSMN1; SMN2NR1H2
SCHEMBL14426353 0.78 KDM4E (0.50) KDM4EALDH1A1POLBSMN1; SMN2NR1H2
SCHEMBL25745797 0.78 NR1H2 (0.54) KDM4EALDH1A1POLBSMN1; SMN2NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-8653087-B2 Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-18 US disclosed
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312939-A1 NEW CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 KDM4E 2715/4885ALDH1A1 175/4885POLB 3682/4885
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS CCNT1, CCNA1, CCND1 KDM4E 1224/4885ALDH1A1 860/4885POLB 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.